PET imaging in testicular tumours

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Testicular cancer incidence is rising, necessitating optimized management strategies.
• Positron Emission Tomography/Computed Tomography (PET/CT) with [18F]fluorodeoxyglucose ([18F]FDG) has a defined role in specific clinical scenarios for testicular cancer.
• Recent advances have expanded the understanding of PET/CT applications in testicular cancer patients.

Purpose of the Study:

• To review recent advancements in the use of [18F]FDG PET/CT for managing testicular cancer patients.
• To clarify the specific clinical settings where PET/CT is beneficial in testicular cancer care.
• To evaluate the diagnostic performance and clinical utility of PET/CT in different testicular cancer subtypes.

Main Methods:

• Review of current literature on [18F]FDG PET/CT in testicular cancer.
• Analysis of PET/CT's role in initial staging, residual mass assessment, and treatment response evaluation.
• Assessment of PET/CT's positive and negative predictive values in various clinical contexts.

Main Results:

• [18F]FDG PET/CT is not recommended for initial staging or suspected testicular tumors.
• PET/CT is primarily valuable for assessing residual seminoma masses larger than 3 cm after therapy.
• Interim PET/CT may help de-escalate chemotherapy in patients achieving remission, thereby reducing toxicity. The sensitivity for teratomas in nonseminoma tumors is limited.

Conclusions:

• [18F]FDG PET/CT is a valuable tool for post-therapy assessment of seminoma residual masses (>3 cm).
• A negative PET/CT scan can potentially spare patients from unnecessary chemotherapy cycles, reducing treatment-related toxicity.
• Careful scheduling and interpretation, considering patient history, are crucial for accurate PET/CT results in testicular cancer management.